Once-Weekly Dulaglutide for Type 2 Diabetes Ups Patient Satisfaction

This article originally appeared here.
Share this content:
Once-Weekly Dulaglutide for Type 2 Diabetes Ups Patient Satisfaction
Once-Weekly Dulaglutide for Type 2 Diabetes Ups Patient Satisfaction

HealthDay News — For patients with type 2 diabetes, treatment satisfaction is improved with once-weekly dulaglutide, according to a study published in Diabetes, Obesity and Metabolism.

Matthew Reaney, from ERT in Peterborough, UK, and colleagues compared satisfaction among patients with type 2 diabetes receiving once-weekly dulaglutide 1.5 and 0.75 mg (Trulicity) with those receiving exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) for 52 weeks.

The researchers identified significant improvements from baseline in total Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) score for dulaglutide (26 and 52 weeks) and exenatide (at 26 weeks) in the AWARD-1 study. Significantly greater improvement was seen for dulaglutide vs placebo (26 weeks) and exenatide (26 and 52 weeks).

Compared with baseline, all groups had lower perceived frequency of hyperglycemia at 26 and 52 weeks; the improvement was greater for dulaglutide and exenatide vs placebo at 26 weeks and for dulaglutide vs exenatide at 26 and 52 weeks. At weeks 26 and 52, significant improvements from baseline were seen for all groups in total DTSQs scores in the AWARD-3 study.

Compared with baseline, the perceived frequency of hyperglycemia was lower for all groups at 26 and 52 weeks; the improvement was greater for dulaglutide vs metformin at 52 weeks.

"Dulaglutide was associated with improvements in treatment satisfaction and a decrease in perceived frequency of hyperglycemia," the researchers wrote.

Disclosures: All authors were employees of Eli Lilly and Company when the work was completed; Eli Lilly manufactures dulaglutide.

Reference

  1. Reaney M et al. Diabetes Obes Metab. 2015;17:896–903.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus